Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome

PHASE2RecruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

March 21, 2022

Primary Completion Date

September 30, 2032

Study Completion Date

September 30, 2045

Conditions
Lynch SyndromeColon CancerColon Neoplasm
Interventions
DRUG

Mesalamine

The IMP will be supplied as sachets with slow-releasing granules.

DRUG

Placebo

The IMP will be supplied as sachets with slow-releasing granules.

Trial Locations (8)

2650

RECRUITING

Hvidovre Hospital, Hvidovre

9000

NOT_YET_RECRUITING

Aalborg University Hospital, Aalborg

416 85

RECRUITING

Sahlgrenska University Hsospital, Gothenburg

205 02

RECRUITING

Skåne University Hospital, Malmo

116 91

RECRUITING

Ersta Hospital/Ersta Diakoni, Stockholm

171 76

ACTIVE_NOT_RECRUITING

Karolinska University Hospital, Stockholm

901 85

RECRUITING

Norrland University Hospital, Umeå

751 85

NOT_YET_RECRUITING

Akademiska hospital, Uppsala

All Listed Sponsors
collaborator

The Swedish Research Council

OTHER_GOV

collaborator

Karolinska Institutet

OTHER

lead

Ann-Sofie Backman

OTHER